|Toxiciy Grade:||4||City/State/Province:||Houston, TX|
|Treatments:||Chemotherapy, Hormone||Hospital:||University of Texas Health Science Center at Houston|
This phase 2 study involved 45 advanced prostate cancer patients with a median patient age of 65 years.
Patients were treated with androgen deprivation therapy and chemotherapy with doxorubicin, ketoconazole, docetaxel, and estramustine.
The most severe toxicities were of grade 4 and included pneumonia, stroke, and neutropenia. Grade 3 increased blood pressure and infection were also reported.
The median overall survival was 53.7 months.
Correspondence: Dr. Robert Amato; email: firstname.lastname@example.org